ASND vs. CERE, LEGN, VKTX, JAZZ, ITCI, CYTK, ELAN, ROIV, BPMC, and IONS
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Blueprint Medicines (BPMC), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry.
Cerevel Therapeutics (NASDAQ:CERE) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Cerevel Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
In the previous week, Ascendis Pharma A/S had 12 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 18 mentions for Ascendis Pharma A/S and 6 mentions for Cerevel Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.91 beat Cerevel Therapeutics' score of 0.17 indicating that Cerevel Therapeutics is being referred to more favorably in the media.
Ascendis Pharma A/S received 255 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 65.50% of users gave Ascendis Pharma A/S an outperform vote.
Cerevel Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S.
Cerevel Therapeutics currently has a consensus target price of $42.67, indicating a potential upside of 1.35%. Ascendis Pharma A/S has a consensus target price of $176.88, indicating a potential upside of 46.03%. Given Cerevel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Cerevel Therapeutics.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cerevel Therapeutics has a net margin of 0.00% compared to Cerevel Therapeutics' net margin of -152.68%. Ascendis Pharma A/S's return on equity of -98.94% beat Cerevel Therapeutics' return on equity.
Summary
Cerevel Therapeutics beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
